Valuation dashboard for Ovid Therapeutics Inc. (OVID) with P/E N/A, P/B 0.96, EV/EBITDA -14.12 and dividend yield 0.00%. DCF, Graham Number and Earnings Power Value models plus sector comparison against other Healthcare companies.
Ovid Therapeutics Inc. is a biopharmaceutical firm dedicated to creating significant treatments for individuals and families impacted by neurological disorders across the United States. The company's robust pipeline features several key therapeutic candidates: OV101, a drug candidate currently undergoing Phase 2A clinical trials for Fragile X syndrome; OV329, an inhibitor targeting GABA aminotransferase, aimed at managing seizures linked to tuberous sclerosis complex and infa...
Analysis Summary
Ovid Therapeutics Inc. reported revenue of $7.3M in the most recent fiscal year, growing at a 5-year CAGR of -10.5%.
Trailing-twelve-month margins: gross margin 100.0%, operating margin -36.9%, net margin -21.8%.
At the current price of $2.68, OVID has negative trailing earnings (P/E not meaningful) and an ROE of -23.64%. Market capitalisation stands at $500M.
Balance sheet quality for OVID: current ratio of 10.9. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Valuation Ratios
| Price / Book | 0.96 |
| EV / EBITDA | -14.12 |
| Dividend Yield | 0.00% |
Peer Comparison
| Symbol | Company | Market Cap | P/E | P/B | ROE |
|---|---|---|---|---|---|
| OVID | Ovid Therapeutics Inc. | $500M | 0.96 | -23.6% | |
| 0QZU.L | Vertex Pharmaceuticals Incorporated | $131.8B | |||
| VRTX | Vertex Pharmaceuticals Incorporated | $130.3B | 29.68 | 6.45 | 23.3% |
| 0R2M.L | Regeneron Pharmaceuticals, Inc. | $84.0B | |||
| REGN | Regeneron Pharmaceuticals, Inc. | $79.8B | 18.79 | 2.57 | 13.8% |
| ARGX | argenx SE | $61.2B | 36.30 | 7.40 | 21.7% |
| MRNA | Moderna, Inc. | $57.8B | 1.34 | -39.2% | |
| RVMD | Revolution Medicines, Inc. | $41.7B | 15.96 | -96.4% |
Price
| Price | $2.68 |
| Market Cap | $500M |
| Exchange | NASDAQ |
| Country | US |
Profitability
| Return on Equity | -23.64% |
| Return on Invested Capital | -26.11% |
| Return on Assets | -14.87% |
| Gross Margin | 100.00% |
| Operating Margin | -3686.67% |
| Net Margin | -2178.90% |
Related companies: CLNN · CNTB · CNTX · IFRX · IMA · KLRS · MGNX
Explore sector: Healthcare · Biotechnology
More sections of OVID: Overview · Financials · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks